Sentences with phrase «against tumor antigens»

Immunity is key to long - term responses Knowing that the immune system is capable of recognizing distinctive features of cancer cells and launching a T cell attack against those tumor antigens, and that checkpoint blockade removes a roadblock to that attack, it's logical that these drugs should work against many tumor types.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

Not exact matches

Different classes of MHC molecules exist and are involved in immunity against pathogens and tumor cells as well as the formation of immune tolerance to self - antigens.

We report here the adoptive transfer, to patients with metastatic melanoma, of highly selected tumor - reactive T cells directed against overexpressed self - derived differentiation antigens after a nonmyeloablative conditioning regimen.

Hu14.18 K332A is a laboratory - produced antibody designed to activate the immune response against tumor cells by recognizing and binding to an antigen found on the surface of most neuroblastoma tumor cells.

The mechanism of action is based on the activation of macrophages to defend against tumors by direct tumor cytotoxicity and consequently they secrete cytokines which recruit secondary immune cells, presenting antigen to T cells [5 - 7].

Cancer vaccines are designed to stimulate an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

While much recent research has not been published in this area, there is actually a long history of studies that show: (1) there is a significant number of antigens shared between tumors and embryonic tissues (called «oncofetal antigens») and, consequently, antibodies made against tumors can also recognize embryonic tissues, and vice versa; (2) pregnancy confers some immunity against cancer (accompanied by antibody production against oncofetal antigens), not only against its occurrence but also against its growth; (3) similar to pregnancy, an immune response against cancer can be generated by vaccinating animals with embryonic tissues.

Therapeutic vaccines are designed to elicit an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

Bryan's group has designed a BiTE against the EGFRvIII tumor - specific antigen, which is expressed in a majority of glioblastoma cases, and has performed preclinical tests to determine its efficacy against EGFRvIII - expressing glioblastoma.

Therapeutic cancer vaccines are designed to elicit an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

Cancer vaccines are designed to elicit an immune response against tumor - specific or tumor - associated antigens.

The difficulty in using monoclonal antibodies against tumor cells is that most of the antibodies raised will be against immunodominant antigens — all the high - visibility proteins that the immune system recognizes.

This approach involves first generating many monoclonal antibodies raised against «crude» tumor cell antigen populations — whole cells and cell membranes — and then screening for those that block the metastatic ability of the cell.

There, they will be exposed to tumor antigens released from dying glioma cells through TK + valacyclovir - induced glioma cell death, and thus mediate a specific anti-malignant glioma immune response against remaining malignant glioma cells.

Low - dose chemotherapy, radiation, or targeted therapies given in combination with immune checkpoint blockade may prove to be an effective and efficient way to immunize the body against tumor cells,» says CRI Scientific Advisory Council associate director James P. Allison, Ph.D., who identified the first immune checkpoint blockade with his discovery in 1995 that the cytotoxic T lymphocyte antigen - 4 (CTLA - 4) receptor inhibited T cell responses.

«We have created a potentially much less expensive approach to making a therapeutic cancer vaccine that, while targeting a single tumor antigen, generates an immune response against multiple antigens.

Also, CMB305 was well tolerated, and generated a strong and broad anti-NY-ESO-1 immune response in > 50 % of the patients, including evidence of antigen spreading — the induction of an immune response against other tumor antigens not targeted by CMB305.